Aspira Women's Health Inc.
AUSTIN, TX · CIK 0000926617 · Medtech · Public
AI-powered diagnostic test for ovarian cancer risk assessment in women with adnexal masses
aspirawh.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $80M
- 7 Form D · Jun 2026
- 3 months since last filing
- Contracts
- $696K
- 4 awards · Defense, Health and Human S
- #355 of 4531 in medtech
- Patents
- 14
- 0 granted · 14 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200420062008201020122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Defense · 200604!600031!2100!W911NF!USA Materiel Command ACQUISITION!W911NF06C0037 !a!n! !n! ! !20051112!20061110!861471498!861471498!861471498!N!CIPHERGEN Biosystems !6611 Dumbarton Cir !fremont !CA!94555!26000!001!06!FREMONT !alameda !CALIFORNIA!+000000365000!N!N!000000730000!AZ11!RDTE/OTHER Research & Development-basic Research !S1 !services !000 !not Discernable !541710!E! !3! ! ! ! ! !999 | $661,640 | |
| Federal contract | Department of Health and Human Services · 000HCC95-2006-28011 - Ciphergen - Laboratory Supplies | $9,415 | |
| Federal contract | Department of Health and Human Services · 000HCRU8-2006-31956.01 - Ciphergen Svc Biomek/whistler | $16,740 | |
| Federal contract | Department of Health and Human Services · 000HCRU8-2006-34986 - Ciphergen/panicker | $8,065 | |
| Private capital raised | Form D · SEC | $43,049,858 | |
| Private capital raised | Form D · SEC | $13,242,500 | |
| Private capital raised | Form D · SEC | $11,025,000 | |
| Private capital raised | Form D · SEC | $6,488,230 | |
| Private capital raised | Form D · SEC | $1,370,000 | |
| Private capital raised | Form D · SEC | $2,950,000 | |
| Private capital raised | Form D · SEC | $1,485,000 |
Federal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 352 | INCLUDEHEALTH, INC. | $715K | — |
| 353 | Konan Medical USA, Inc. | $714K | $6.0M |
| 354 | NANODROPPER INC | $712K | $1.1M |
| 355 | Aspira Women's Health Inc. | $696K | $80M |
| 356 | BIOPTIGEN, INC. | $686K | $1.5M |
| 357 | ISOPLEXIS CORPORATION | $684K | $127M |
| 358 | TearScience, Inc. | $681K | $59M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- ELLEN BEAUSANGDirector
- Robert BeecheyExecutive Officer
- Jody BerryExecutive Officer
- MICHAEL BUHLEExecutive Officer
- James BurnsDirector
- Stefanie CavanaughDirector
- STEFANIE CAVANAUGHDirector
- Nancy CocozzaDirector
- JEFFREY COHENDirector
- JAMES CRAWFORDExecutive Officer
- William CreechExecutive Officer
- Celeste FralickDirector
- CELESTE FRALICKDirector
- JACK FRASERDirector
- JOHN FRASERDirector · Executive Officer
- Robert GogginDirector
- John HamiltonDirector
- Jannie HerchukDirector
- JANNIE HERCHUKDirector
- Torsten HombeckExecutive Officer
- Bruce HuebnerDirector
- CYNTHIA HUNDORFEANDirector
- BRIAN HUNGERFORDExecutive Officer
- Veronica JordanDirector
- James LaFranceDirector
- Thomas McLainExecutive Officer
- Minh MerchantExecutive Officer
- Donald MunroeExecutive Officer
- Lynn O'Connor VosDirector
- ELLEN O'CONNOR-VOSDirector
- Gail PageDirector
- Valerie PalmieriDirector · Executive Officer
- Winfred ParnellDirector
- WINFRED PARNELLDirector
- JOHN RAGARDDirector
- Peter RoddyDirector
- Nicole SandfordDirector · Executive Officer
- Eric SchoenExecutive Officer
- David SchreiberDirector
- Carl SeveringhausDirector
- JOHN STRAHLEYExecutive Officer
- William WallenDirector
- Jane WOODDirector
Patents
- Compositions For Endometriosis Assessment Having Improved Specificityapplication
- Compositions For Ovarian Cancer Assessment Having Improved Specificity And Sensitivityapplication
- Compositions For Endometriosis Assessment Having Improved Specificityapplication
- Compositions For Ovarian Cancer Assessmentapplication
- Predictive Biomarkers For Ovarian Cancerapplication
- Methods For Characterizing Ovarian Cancerapplication
- Compositions For Ovarian Cancer Assessment Having Improved Specificity And Sensitivityapplication
- Compositions For Endometriosis Assessment Having Improved Specificityapplication
- Compositions For Endometriosis Assessment Having Improved Specificityapplication
- Compositions For Ovarian Cancer Assessmentapplication
- Compositions For Endometriosis Assessment Having Improved Specificityapplication
- Methods For Characterizing An Adnexal Massapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.